12:00 AM
 | 
Feb 11, 2008
 |  BioCentury  |  Strategy

Tapping Amgen

Tapping Amgen

Tapping Amgen
Amgen (NASDAQ:AMGN) has granted Takeda (Tokyo:4502) Japanese rights to 12 biologics and global rights to a small molecule VEGF inhibitor. Not all the molecules have been identified, but they do include the...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >